Company Filing History:
Years Active: 2017
Title: Shivakeshava Gaddam: Innovator in Cancer Research
Introduction
Shivakeshava Gaddam is a notable inventor based in Tyler, Texas. He has made significant contributions to the field of cancer research, particularly in understanding malignant pleural mesothelioma (MPM). His innovative work focuses on the role of endothelial protein C receptors in tumor growth suppression.
Latest Patents
Gaddam holds a patent titled "Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein C receptors (EPCR)." This patent discloses the influence of tissue factor (TF), EPCR, and protease-activated receptor-1 (PAR1) on the tumor growth of MPM. His research revealed that MPM cells lacking or expressing TF, EPCR, or PAR1, along with a murine orthotopic model of MPM, led to significant findings. The study demonstrated that intrapleural administration of REN MPM cells expressing TF and PAR1 but lacking EPCR and PAR2 resulted in large pleural cavity tumors. Notably, suppression of TF or PAR1 expression markedly reduced tumor growth. Furthermore, overexpression of TF in non-aggressive MPM cells expressing EPCR and PAR1 did not alter their tumorigenicity. The introduction of EPCR expression in aggressive MPM cells attenuated tumor growth, while EPCR silencing in non-aggressive MPM cells overexpressing TF increased their tumorigenicity. Overall, the expression of EPCR by MPM cells plays a crucial role in suppressing tumor growth and treating MPM.
Career Highlights
Gaddam is affiliated with the University of Texas System, where he continues to advance his research in cancer biology. His work has garnered attention for its potential implications in therapeutic strategies for MPM.
Collaborations
Gaddam has collaborated with esteemed colleagues, including Usha R Pendurthi and Vijaya M R Lella, contributing to the collective knowledge in the field of cancer research.
Conclusion
Shivakeshava Gaddam's innovative research and patent contributions significantly enhance our understanding of malignant pleural mesothelioma and its treatment. His work exemplifies the impact of scientific inquiry on advancing medical knowledge and therapeutic options.